Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis - Wikidata - wikimedia - TriplyDB

Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

http://www.wikidata.org/entity/Q21195369

about

Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis.Spondyloarthritides: evolving therapies Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey.Simultaneous multioutcome synthesis and mapping of treatment effects to a common scale.The joint-gut axis in inflammatory bowel diseases.Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylos Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.Randomized, placebo controlled and double-blind trials of efficacy and safety of adalimumab for treating ankylosing spondylitis: a meta-analysis.Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review.Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy.Recommendations for the management and treatment of ankylosing spondylitis.Treatment efficacy of etanercept and MTX combination therapy for ankylosing spondylitis hip joint lesion in Chinese population.Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.Continuous Improvement of Physical Functioning in Ankylosing Spondylitis Patients by Tumor Necrosis Factor Inhibitors: Three-Year Followup and Predictors.[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures].IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis.Optimizing outcomes for ankylosing spondylitis and axial spondyloarthritis patients: a holistic approach to care

P2860

Q34570563-10A898F6-645B-4A6E-B8D8-C31F12BFA655 Q34613907-4924972D-4365-4C2F-B218-CF8B247F5345 Q35759171-FAE2F80F-3E37-46A5-AF8C-A08F39E459BC Q35896670-155140FE-A769-4340-93EE-05A12CD22A0A Q36758296-4E07E9BF-EF19-464A-BDF5-7318055429D3 Q37709832-875B1CF1-168A-4965-AB09-AB16E216A200 Q37814551-07A0E103-07AF-480F-A1A6-6D06FB5D4F2C Q37873493-A1894E88-E139-4F3D-98E0-5A9174472C08 Q38010372-BBCE00E2-23CA-4A30-A578-B39B744D6251 Q38145501-DABF18B0-7FBA-41E0-A8CA-1E2234DAD504 Q38186145-6C1D9404-D2A4-4965-AE4E-F5A49589E215 Q38246381-940D24B0-6E48-4D8A-8A3F-5D6F7948C7EC Q38972623-E5A1F277-7E2A-4B4D-B611-A733CB6B3536 Q43233004-13D23D8E-5655-4A49-8052-10F6B77BA62C Q44898441-E4F94CA4-683A-4C8A-90E7-C8A2E4EF48BD Q44925976-7E16E0EE-94A8-4BE5-9169-5723BE37B7A0 Q47561517-9B80EBC6-E085-477A-8A3B-3601DD51719E Q48282725-0B54C333-2BA4-45A2-A052-C8BD59DCE89B Q49432593-FFD5C31B-9DAF-484C-986A-9977157845C0 Q50879886-144D3AC9-3832-4F30-BAF8-729A28464845 Q52874129-2CDF1370-88F4-4BD5-9A58-B79067E92FBE Q54976780-8EFBCBFA-5BA8-4ABA-9CB5-1DBCFB737BB0 Q59125381-02ED0216-AB14-421E-A0CC-09F211723333

P2860

Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

http://www.wikidata.org/entity/Q21195369

description

2009 nî lūn-bûn

@nan

2009 թուականին հրատարակուած գիտական յօդուած

@hyw

2009 թվականին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Physical function, disease act ...... ts with ankylosing spondylitis

@ast

Physical function, disease act ...... ts with ankylosing spondylitis

@en

Physical function, disease act ...... ts with ankylosing spondylitis

@en-gb

Physical function, disease act ...... ts with ankylosing spondylitis

@nl

type

label

Physical function, disease act ...... ts with ankylosing spondylitis

@ast

Physical function, disease act ...... ts with ankylosing spondylitis

@en

Physical function, disease act ...... ts with ankylosing spondylitis

@en-gb

Physical function, disease act ...... ts with ankylosing spondylitis

@nl

prefLabel

Physical function, disease act ...... ts with ankylosing spondylitis

@ast

Physical function, disease act ...... ts with ankylosing spondylitis

@en

Physical function, disease act ...... ts with ankylosing spondylitis

@en-gb

Physical function, disease act ...... ts with ankylosing spondylitis

@nl

P1433

Q21195369-45C09921-D49C-4B0C-BFB9-C3608F431EE1

P1476

Q21195369-0CC366EB-0D90-4D7B-8D08-6F93FF67FAC0

P2093

Q21195369-18CD4F5F-BA70-49AB-8FC2-2F33EC02A0FD

Q21195369-64D3F72A-AA19-4E34-BD59-88991F5F4B4D

Q21195369-79AB4110-B938-45A5-B9D5-73F8DCAB92F8

Q21195369-809FAD9E-6CF6-4C6E-8C2A-F64D713F7562

Q21195369-82740CF2-B665-4D32-A772-3AA791C19E2B

Q21195369-93118633-C451-4FDB-B1B3-0D0865BC0C1D

Q21195369-9FF3A26C-6097-49A7-ADE8-4E5AA2076264

Q21195369-F4D6992B-493F-4922-9E78-DDE34D5CA6CF

P2860

Q21195369-03F1B590-0DF3-437D-BAF7-5DC1AC255929

Q21195369-0FC1BF27-7511-4269-BA51-68F38AAED12B

Q21195369-201A7223-C2F8-4ADF-9584-B6DA21EF312D

Q21195369-3EB36E13-137E-4667-8D4C-06B53C5033CB

Q21195369-531DD06A-97E6-435D-A46F-30FD062A3FD5

Q21195369-59EE1261-E373-4A6F-B720-6D3CE8CAA9D3

Q21195369-615451E9-B3E9-4CCE-8A1D-8050BF9DECAD

Q21195369-66B93B47-C874-40AB-8606-93AC00D4B8C8

Q21195369-6BA87EA1-D231-4927-803C-DF5912995676

Q21195369-6F73EABD-BA52-4EE7-A1F1-617A3E9A88D9

P2888

Q21195369-8AE61B09-2476-4470-AB12-92D1CB274F58

P304

Q21195369-622B8E24-DAD2-4385-ACD4-D1578D781BDD

P31

Q21195369-BC76F4E9-CDDF-4D2D-B303-34A47D4978E2

P3181

Q21195369-411791F1-3B87-4358-B8C7-97E83B6DE93F

P356

Q21195369-6F7952DB-0EBE-435E-B904-84347E7D0157

P407

Q21195369-438AC329-D453-4493-A829-729943A5FE73

P433

Q21195369-98BC331A-5463-4F7A-8F8A-C927A04F5A8C

P478

Q21195369-8CA733E5-E59A-4B57-8DBD-1E23D840FFE9

P577

Q21195369-28AA9873-8E15-42B6-B370-8A789072CB0F

P5875

Q21195369-2C4E0022-887F-4030-BF99-1E7F9FB7E170

P698

Q21195369-E07875FF-A8A0-4B21-BBAB-B51097FE0BE0

P921

Q21195369-23F9CD17-5364-4009-8816-1CEBEE81FD09

Q21195369-7485D09D-6F17-4DD7-8DF3-74EE8EEFF749

Q21195369-A6508E74-F212-49F5-8DD8-3341918B0F46

P932

Q21195369-D7A4706A-6746-428E-9E75-29E9E119E0AF

P3181

P356

P1433

Arthritis Research and Therapy

P1476

Physical function, disease act ...... ts with ankylosing spondylitis

@en

P2093

Chris Thompson

http://www.w3.org/2001/XMLSchema#string

Dennis A Revicki

http://www.w3.org/2001/XMLSchema#string

Désirée M van der Heijde

http://www.w3.org/2001/XMLSchema#string

Hartmut Kupper

http://www.w3.org/2001/XMLSchema#string

Joachim Sieper

http://www.w3.org/2001/XMLSchema#string

Katherine L Gooch

http://www.w3.org/2001/XMLSchema#string

Neesha Harnam

http://www.w3.org/2001/XMLSchema#string

Robert L Wong

http://www.w3.org/2001/XMLSchema#string

P2860

Six months open label trial of leflunomide in active ankylosing spondylitis

Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index

Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.

Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis.

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.

P2888

P304

R124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4943170

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/AR2790

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26747670

http://www.w3.org/2001/XMLSchema#string

P698

19686597

http://www.w3.org/2001/XMLSchema#string

P921

quality of life

P932

2745808

http://www.w3.org/2001/XMLSchema#string